淋巴细胞胞质蛋白2在恶性肿瘤发生与发展过程中的免疫调节机制
The Immune Regulatory Mechanism of Lymphocyte Cytoplasmic Protein 2(LCP2)in the Occurrence and Development of Malignant Tumors
魏琳 1韩英伦 2刘欣2
作者信息
- 1. 辽宁师范大学生命科学学院七鳃鳗研究中心,辽宁,大连 116029
- 2. 辽宁师范大学生命科学学院七鳃鳗研究中心,辽宁,大连 116029;大连工业大学海洋食品精深加工关键技术省部共建协同创新中心,辽宁,大连 116034
- 折叠
摘要
淋巴细胞胞质蛋白2(lymphocyte cytosolic protein 2,LCP2)是一种衔接蛋白质,在T细胞受体信号通路中扮演重要角色,激活下游信号因子以完成机体的免疫应答过程.LCP2也在恶性肿瘤的发生发展与转移中发挥重要作用,其高表达会导致不良的预后效果,降低患者生存率,其具体作用机制涉及多条信号通路.本文不仅对LCP2 的分子结构以及基本功能进行了介绍,而且重点综合评述了LCP2通过参与NF-κB、MAPK、JAK/STAT 以及PD-1/PD-L1 信号通路调控恶性肿瘤发生与发展的分子机制.总结了LCP2作为肿瘤治疗靶点的潜在作用,为将来用于相关疾病的诊断、治疗和标志物筛选等提供理论基础和参考依据.
Abstract
Lymphocyte cytoplasmic protein 2(LCP2)is an adaptor protein that participates in the T cell receptor signal transduction pathway through activating downstream signaling factors to complete the im-mune response.LCP2 also plays an important role in the occurrence,development and metastasis of ma-lignant tumors.The high expression of LCP2 leads to adverse prognostic effects and reduces patient sur-vival rates.The specific mechanisms of these reactions involve multiple signaling pathways.Here we in-troduce the structure and basic functions of LCP2,and review the important roles that LCP2 plays in the occurrence and development of malignant tumors through participating in NF-κB,MAPK,JAK/STAT,and PD-1/PD-L1 signaling pathways.The potential role of LCP2 as a tumor treatment target was also dis-cussed for providing a theoretical basis and reference for the diagnosis,treatment,and biomarker screen-ing of relevant diseases.
关键词
淋巴细胞胞质蛋白2/衔接蛋白质/信号通路/恶性肿瘤Key words
lymphocyte cytoplasmic protein 2(LCP2)/adaptor protein/signaling pathway/malignant tumor引用本文复制引用
基金项目
辽宁省兴辽英才计划(XLYC2007189)
辽宁省教育厅科研项目(LJKZ0990)
国家自然科学基金(32270557)
出版年
2024
NETL
NSTL
维普
万方数据